Year |
Citation |
Score |
2020 |
Hanson A, Elpek K, Duong E, Shallberg L, Fan M, Johnson C, Wallace M, Mabry GR, Sazinsky S, Pepper L, Shu CJ, Sathyanarayanan S, Zuerndorfer S, Simpson T, Gostissa M, et al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. Plos One. 15: e0239595. PMID 32970735 DOI: 10.1371/journal.pone.0239595 |
0.376 |
|
2020 |
Shamah S, Elpek K, Ezell T, Fleury M, Gallo M, Gori J, Heller S, Inniss M, Langley M, Olinger G, Richardson C, Tran K, Sethi D, Sun D, Suri V. Abstract 6604: Drug responsive domain regulation of IL15-engineered T cells provides pharmacological control over antigen-independent cell expansion Immunology. DOI: 10.1158/1538-7445.Am2020-6604 |
0.399 |
|
2019 |
Tran K, Elpek K, Ezell T, Heller S, Inniss M, Kulkarni A, Li DJ, Olinger G, Ols M, Reardon C, Sun D, Kassum T, Briskin M, Richardson C, Suri V, et al. Abstract A220: Destabilizing domain technology facilitates exogenous regulation of IL15 and IL12 for adaptive T-cell therapy Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A220 |
0.466 |
|
2019 |
Ols M, Schebesta M, Brideau E, Elpek K, Fleury M, Gori J, Heller S, Li DJ, Primack B, Reardon C, Sethi D, Storer A, Sun D, Tran K, Weisman E, et al. Abstract LB-013: CAR-Ts armored with small molecule-regulated IL12 or CD40L cassettes for enhanced activity against solid tumors Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-013 |
0.515 |
|
2018 |
Richardson C, Elpek K, Ols M, Kassum T, Shamah S. Abstract 3580: Enhancing adoptive cell therapies through exogenous regulation Immunology. DOI: 10.1158/1538-7445.Am2018-3580 |
0.314 |
|
2017 |
Michaelson JS, Harvey C, Elpek K, Duong E, Shallberg L, Wallace M, Mabry R, Shu J, Deshpande A, Zi T, Sazinsky S, Apgar J, Mounho-Zamora B, Briskin M, Trehu E, et al. Abstract SY03-02: Preclinical assessment of JTX-2011, an agonist antibody targeting ICOS, supports evaluation in ICONIC clinical trial Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Sy03-02 |
0.477 |
|
2016 |
Elpek K, Harvey C, Duong E, Simpson T, Shu J, Shallberg L, Wallace M, Sathy S, Mabry R, Michaelson J, Briskin M. Abstract A059: Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A059 |
0.508 |
|
2016 |
Michaelson JS, Harvey CJ, Elpek KG, Duong E, Wallace M, Shu CJ, Sathyanarayanan S, Mabry R, Shallberg L, Zi T, Deshpande A, Sazinsky SL, Apgar J, Law D. Abstract 573: Preclinical evaluation of JTX-2011, an anti-ICOS agonist antibody Cancer Research. 76: 573-573. DOI: 10.1158/1538-7445.Am2016-573 |
0.448 |
|
2015 |
Platzer B, Elpek KG, Cremasco V, Baker K, Stout MM, Schultz C, Dehlink E, Shade KT, Anthony RM, Blumberg RS, Turley SJ, Fiebiger E. IgE/FcεRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses. Cell Reports. PMID 25753415 DOI: 10.1016/J.Celrep.2015.02.015 |
0.516 |
|
2015 |
Harvey C, Elpek K, Duong E, Simpson T, Shu CJ, Shallberg L, Wallace M, Sathyanarayanan S, Mabry R, Briskin M, Michaelson J, Gajewski TF. Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-O9 |
0.525 |
|
2014 |
Elpek KG, Cremasco V, Shen H, Harvey CJ, Wucherpfennig KW, Goldstein DR, Monach PA, Turley SJ. The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells. Cancer Immunology Research. 2: 655-67. PMID 24801837 DOI: 10.1158/2326-6066.Cir-13-0209 |
0.42 |
|
2014 |
Zhou P, Shaffer DR, Alvarez Arias DA, Nakazaki Y, Pos W, Torres AJ, Cremasco V, Dougan SK, Cowley GS, Elpek K, Brogdon J, Lamb J, Turley SJ, Ploegh HL, Root DE, et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature. 506: 52-7. PMID 24476824 DOI: 10.1038/Nature12988 |
0.423 |
|
2014 |
Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu S, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, et al. GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition Blood. 124: 3567-3567. DOI: 10.1182/Blood.V124.21.3567.3567 |
0.399 |
|
2013 |
Mingueneau M, Kreslavsky T, Gray D, Heng T, Cruse R, Ericson J, Bendall S, Spitzer MH, Nolan GP, Kobayashi K, von Boehmer H, Mathis D, Benoist C, Best AJ, ... ... Elpek K, et al. The transcriptional landscape of αβ T cell differentiation. Nature Immunology. 14: 619-32. PMID 23644507 DOI: 10.1038/Ni.2590 |
0.386 |
|
2012 |
Acton SE, Astarita JL, Malhotra D, Lukacs-Kornek V, Franz B, Hess PR, Jakus Z, Kuligowski M, Fletcher AL, Elpek KG, Bellemare-Pelletier A, Sceats L, Reynoso ED, Gonzalez SF, Graham DB, et al. Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity. 37: 276-89. PMID 22884313 DOI: 10.1016/J.Immuni.2012.05.022 |
0.38 |
|
2012 |
Miller JC, Brown BD, Shay T, Gautier EL, Jojic V, Cohain A, Pandey G, Leboeuf M, Elpek KG, Helft J, Hashimoto D, Chow A, Price J, Greter M, Bogunovic M, et al. Deciphering the transcriptional network of the dendritic cell lineage. Nature Immunology. 13: 888-99. PMID 22797772 DOI: 10.1038/Ni.2370 |
0.392 |
|
2012 |
Malhotra D, Fletcher AL, Astarita J, Lukacs-Kornek V, Tayalia P, Gonzalez SF, Elpek KG, Chang SK, Knoblich K, Hemler ME, Brenner MB, Carroll MC, Mooney DJ, Turley SJ. Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nature Immunology. 13: 499-510. PMID 22466668 DOI: 10.1038/Ni.2262 |
0.387 |
|
2011 |
Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, Fletcher-Sananikone E, Zhang H, Liu Y, Wang W, Ren X, Zheng H, Kimmelman AC, Paik JH, Lim C, et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discovery. 1: 158-69. PMID 21984975 DOI: 10.1158/2159-8290.Cd-11-0031 |
0.361 |
|
2011 |
Lukacs-Kornek V, Malhotra D, Fletcher AL, Acton SE, Elpek KG, Tayalia P, Collier AR, Turley SJ. Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nature Immunology. 12: 1096-104. PMID 21926986 DOI: 10.1016/J.Niox.2012.04.032 |
0.41 |
|
2011 |
Elpek KG, Bellemare-Pelletier A, Malhotra D, Reynoso ED, Lukacs-Kornek V, DeKruyff RH, Turley SJ. Lymphoid organ-resident dendritic cells exhibit unique transcriptional fingerprints based on subset and site. Plos One. 6: e23921. PMID 21886840 DOI: 10.1371/Journal.Pone.0023921 |
0.356 |
|
2011 |
Takeda Y, Li Q, Kazarov AR, Epardaud M, Elpek K, Turley SJ, Hemler ME. Diminished metastasis in tetraspanin CD151-knockout mice. Blood. 118: 464-72. PMID 21536858 DOI: 10.1182/Blood-2010-08-302240 |
0.466 |
|
2010 |
Elpek KG, Rubinstein MP, Bellemare-Pelletier A, Goldrath AW, Turley SJ. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proceedings of the National Academy of Sciences of the United States of America. 107: 21647-52. PMID 21098276 DOI: 10.1073/Pnas.1012128107 |
0.438 |
|
2010 |
Turley SJ, Fletcher AL, Elpek KG. The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs. Nature Reviews. Immunology. 10: 813-25. PMID 21088682 DOI: 10.1038/Nri2886 |
0.462 |
|
2010 |
Sharma RK, Yolcu ES, Elpek KG, Shirwan H. Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy. Cancer Gene Therapy. 17: 730-41. PMID 20559332 DOI: 10.1038/Cgt.2010.29 |
0.667 |
|
2010 |
Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ, Yolcu ES, Shirwan H. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Research. 70: 3945-54. PMID 20406989 DOI: 10.1158/0008-5472.Can-09-4480 |
0.728 |
|
2010 |
Elpek KG, Rubinstein MP, Bellemare-Pelletier A, Goldrath AW, Turley SJ. Abstract 3829: Chronic stimulation with IL-15/IL-15Rα complexes leads to NK cell dysfunction Cancer Research. 70: 3829-3829. DOI: 10.1158/1538-7445.Am10-3829 |
0.479 |
|
2010 |
Sharma RK, Schabowsky R, Srivastava AK, Yolcu ES, Elpek KG, Zhao H, Madireddi S, Shirwan H. Abstract 2416: SA-4-1BBL costimulatory ligand as an immune modulator and effective vehicle to deliver antigens into dendritic cells for the generation of robust therapeutic antitumor immune responses Cancer Research. 70: 2416-2416. DOI: 10.1158/1538-7445.Am10-2416 |
0.717 |
|
2010 |
Sharma RK, Yolcu ES, Elpek KG, Shirwan H. Abstract 1501: Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy Cancer Research. 70: 1501-1501. DOI: 10.1158/1538-7445.Am10-1501 |
0.633 |
|
2010 |
Sharma R, Schabowsky R, Srivastava A, Yolcu E, Elpek K, Zhao H, Madireddi S, Shirwan H. SA-4-1BBL Serves as an Immune Modulator as well as Vehicle to Deliver Antigens into Dendritic Cells in vivo for Generation of Robust Immunity for Eradication of Tumors Clinical Immunology. 135: S86. DOI: 10.1016/J.Clim.2010.03.258 |
0.629 |
|
2009 |
Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, Bandura-Morgan L, Miller R, MacLeod KJ, Mittler RS, Shirwan H. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine. 28: 512-22. PMID 19836479 DOI: 10.1016/J.Vaccine.2009.09.127 |
0.648 |
|
2009 |
Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, Bandura-Morgan L, Shirwan H. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Research. 69: 4319-26. PMID 19435920 DOI: 10.1158/0008-5472.Can-08-3141 |
0.712 |
|
2009 |
Reynoso ED, Elpek KG, Francisco L, Bronson R, Bellemare-Pelletier A, Sharpe AH, Freeman GJ, Turley SJ. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. Journal of Immunology (Baltimore, Md. : 1950). 182: 2102-12. PMID 19201863 DOI: 10.4049/Jimmunol.0802769 |
0.387 |
|
2008 |
Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, Hamerman JA, Goldrath AW, Turley SJ. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Research. 68: 2972-83. PMID 18413767 DOI: 10.1158/0008-5472.Can-08-0045 |
0.445 |
|
2008 |
Sharma R, Elpek K, Yolcu E, Schabowsky R, Zhao H, Bandura-Morgon L, Shirwan H. Su.60. A Novel Vaccine Concept for Treatment of Cervical Cancer Clinical Immunology. 127: S143-S144. DOI: 10.1016/J.Clim.2008.03.411 |
0.589 |
|
2007 |
Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. Journal of Immunology (Baltimore, Md. : 1950). 179: 7295-304. PMID 18025172 DOI: 10.4049/Jimmunol.179.11.7295 |
0.7 |
|
2007 |
Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. Journal of Immunology (Baltimore, Md. : 1950). 178: 6840-8. PMID 17513732 DOI: 10.4049/Jimmunol.178.11.6840 |
0.688 |
|
2007 |
Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, Shirwan H, Sam Zhou H, McMasters KM. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunology, Immunotherapy : Cii. 56: 997-1007. PMID 17146630 DOI: 10.1007/S00262-006-0247-2 |
0.596 |
|
2005 |
Köksoy S, Elpek KG, Yolcu ES, Shirwan H. Tolerance to rat heart grafts induced by intrathymic immunomodulation is mediated by indirect recognition primed CD4+CD25+ Treg cells. Transplantation. 79: 1492-7. PMID 15940037 DOI: 10.1097/01.Tp.0000159870.01567.02 |
0.634 |
|
Show low-probability matches. |